Compare Stocks: PFNX and BIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIO Bio-Rad Laboratories	$362.68 -0.3%	$372.81	$236.73 ▼ $396.23	$9.70B	1.07	310,798 shs	89,043 shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIO Bio-Rad Laboratories	-0.01%	-1.16%	-1.25%	+23.03%	+20.03%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIO Bio-Rad Laboratories	$362.68 -0.3%	$372.81	$236.73 ▼ $396.23	$9.70B	1.07	310,798 shs	89,043 shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIO Bio-Rad Laboratories	-0.01%	-1.16%	-1.25%	+23.03%	+20.03%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIO Bio-Rad Laboratories	2.20	Hold	$343.33	-5.43% Downside
PFNX Pfenex	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PFNX and BIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	BIO Bio-Rad Laboratories	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
8/17/2026	BIO Bio-Rad Laboratories	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Hold (C-)
8/11/2026	BIO Bio-Rad Laboratories	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/5/2026	BIO Bio-Rad Laboratories	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral ➝ Hold	$300.00 ➝ $330.00
8/5/2026	BIO Bio-Rad Laboratories	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$320.00 ➝ $370.00
8/5/2026	BIO Bio-Rad Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$310.00 ➝ $330.00
8/3/2026	BIO Bio-Rad Laboratories	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIO Bio-Rad Laboratories	$2.58B	3.76	$9.99 per share	36.36	$276.16 per share	1.31
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIO Bio-Rad Laboratories	$759.90M	$8.25	43.98	40.84	N/A	8.59%	3.54%	2.48%	10/29/2026 (Estimated)
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest PFNX and BIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
10/29/2026	Q3 2026	BIO Bio-Rad Laboratories	$2.23	N/A	N/A	N/A	$649.94 million	N/A
8/4/2026	Q2 2026	BIO Bio-Rad Laboratories	$1.75	$2.62	+$0.87	$13.85	$623.99 million	$651.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIO Bio-Rad Laboratories	N/A	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIO Bio-Rad Laboratories	0.11	3.14	2.33
PFNX Pfenex	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIO Bio-Rad Laboratories	65.24%
PFNX Pfenex	N/A

Insider Ownership

Company	Insider Ownership
BIO Bio-Rad Laboratories	30.34%
PFNX Pfenex	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIO Bio-Rad Laboratories	7,450	26.74 million	18.63 million	Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable

PFNX and BIO Headlines

Recent News About These Companies

UCB posts more supportive data from Humira rival bimekizumab

November 6, 2024 | pharmaphorum.comP

NKY Medical Holdings Ltd Class A 300109

January 31, 2024 | morningstar.comM

Last available seats at PFS West Coast Conference next week

May 19, 2023 | pharmaphorum.comP

Ligand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best Stocks

May 4, 2023 | news.google.comN

150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal

April 12, 2023 | news.google.comN

Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio - Nasdaq

April 6, 2023 | news.google.comN

LENZ Therapeutics Closes $83.5M Series B - San Diego Business Journal

March 29, 2023 | news.google.comN

Ranibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital Journal

March 17, 2023 | news.google.comN

Global Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswire

March 15, 2023 | news.google.comN

San Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-Tribune

March 15, 2023 | news.google.comN

Osteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital Journal

March 13, 2023 | news.google.comN

Current and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPR

March 1, 2023 | news.google.comN

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield Californian

February 23, 2023 | news.google.comN

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - Business Wire

February 22, 2023 | news.google.comN

February 8, 2023 | news.google.comN

Osteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital Journal

February 7, 2023 | news.google.comN

Injectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.com

January 27, 2023 | news.google.comN

Osteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital Journal

January 27, 2023 | news.google.comN

Injectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPR

January 6, 2023 | news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFNX and BIO Company Descriptions

Bio-Rad Laboratories NYSE:BIO

$362.68 -1.06 (-0.29%)

As of 02:06 PM Eastern

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)

As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFNX and BIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFNX and BIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFNX and BIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFNX and BIO Company Descriptions

Bio-Rad Laboratories NYSE:BIO

Pfenex NYSEAMERICAN:PFNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFNX and BIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFNX and BIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFNX and BIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFNX and BIO Company Descriptions

Bio-Rad Laboratories NYSE:BIO

Pfenex NYSEAMERICAN:PFNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools